Your shopping cart is currently empty

MY17 is an inhibitor of protein tyrosine phosphatase 1B (PTP1B) with an IC50 of 0.41±0.05 μM. It alleviates insulin resistance induced by palmitic acid (PA) by enhancing the expression of phosphorylated insulin receptor substrate (IRS1) and protein kinase B (AKT). By binding to PTP1B, MY17 inhibits its activity, thereby improving insulin signaling and exhibiting antidiabetic properties. MY17 is useful in the study of type 2 diabetes.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | MY17 is an inhibitor of protein tyrosine phosphatase 1B (PTP1B) with an IC50 of 0.41±0.05 μM. It alleviates insulin resistance induced by palmitic acid (PA) by enhancing the expression of phosphorylated insulin receptor substrate (IRS1) and protein kinase B (AKT). By binding to PTP1B, MY17 inhibits its activity, thereby improving insulin signaling and exhibiting antidiabetic properties. MY17 is useful in the study of type 2 diabetes. |
| Formula | C21H13N5O3S3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.